Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 168

1.

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib.

Kumar SK, LaPlant B, Roy V, Reeder CB, Lacy MQ, Gertz MA, Laumann K, Thompson MA, Witzig TE, Buadi FK, Rivera CE, Mikhael JR, Bergsagel PL, Kapoor P, Hwa L, Fonseca R, Stewart AK, Chanan-Khan A, Rajkumar SV, Dispenzieri A.

Blood Cancer J. 2015 Aug 14;4:e338. doi: 10.1038/bcj.2015.60.

PMID:
26275080
2.

Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement.

Dispenzieri A, Buadi F, Kumar SK, Reeder CB, Sher T, Lacy MQ, Kyle RA, Mikhael JR, Roy V, Leung N, Grogan M, Kapoor P, Lust JA, Dingli D, Go RS, Hwa YL, Hayman SR, Fonseca R, Ailawadhi S, Bergsagel PL, Chanan-Khan A, Rajkumar SV, Russell SJ, Stewart K, Zeldenrust SR, Gertz MA.

Mayo Clin Proc. 2015 Aug;90(8):1054-81. doi: 10.1016/j.mayocp.2015.06.009.

PMID:
26250727
3.

Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma.

Calcinotto A, Ponzoni M, Ria R, Grioni M, Cattaneo E, Villa I, Sabrina Bertilaccio MT, Chesi M, Rubinacci A, Tonon G, Bergsagel PL, Vacca A, Bellone M.

Oncoimmunology. 2015 May 7;4(6):e1008850. eCollection 2015 Jun.

PMID:
26155424
4.

Immunosurveillance and therapy of multiple myeloma are CD226 dependent.

Guillerey C, Ferrari de Andrade L, Vuckovic S, Miles K, Ngiow SF, Yong MC, Teng MW, Colonna M, Ritchie DS, Chesi M, Bergsagel PL, Hill GR, Smyth MJ, Martinet L.

J Clin Invest. 2015 Jul 1;125(7):2904. doi: 10.1172/JCI82646. Epub 2015 Jun 15. No abstract available.

PMID:
26075821
5.

Advances in the pathogenesis and diagnosis of multiple myeloma.

Chesi M, Bergsagel PL.

Int J Lab Hematol. 2015 May;37 Suppl 1:108-14. doi: 10.1111/ijlh.12360.

PMID:
25976968
6.

Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma.

Jensen JL, Rakhmilevich A, Heninger E, Broman AT, Hope C, Phan F, Miyamoto S, Maroulakou I, Callander N, Hematti P, Chesi M, Bergsagel PL, Sondel P, Asimakopoulos F.

Cancer Immunol Res. 2015 Aug;3(8):881-90. doi: 10.1158/2326-6066.CIR-15-0025-T. Epub 2015 May 4.

PMID:
25941352
7.

Immunosurveillance and therapy of multiple myeloma are CD226 dependent.

Guillerey C, Ferrari de Andrade L, Vuckovic S, Miles K, Ngiow SF, Yong MC, Teng MW, Colonna M, Ritchie DS, Chesi M, Bergsagel PL, Hill GR, Smyth MJ, Martinet L.

J Clin Invest. 2015 May;125(5):2077-89. doi: 10.1172/JCI77181. Epub 2015 Apr 20.

8.

Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation.

Roy V, Stewart AK, Bergsagel PL, Dispenzieri A, Laumann K, Allred J, Lacy MQ, Fonseca R, Reeder CB, Kumar S, Rivera CE, Gertz MA, Buadi FK, Hayman SR, Rajkumar SV.

Blood Cancer J. 2015 Mar 20;5:e294. doi: 10.1038/bcj.2015.23. No abstract available.

9.

Che-1-induced inhibition of mTOR pathway enables stress-induced autophagy.

Desantis A, Bruno T, Catena V, De Nicola F, Goeman F, Iezzi S, Sorino C, Ponzoni M, Bossi G, Federico V, La Rosa F, Ricciardi MR, Lesma E, De Meo PD, Castrignanò T, Petrucci MT, Pisani F, Chesi M, Bergsagel PL, Floridi A, Tonon G, Passananti C, Blandino G, Fanciulli M.

EMBO J. 2015 May 5;34(9):1214-30. doi: 10.15252/embj.201489920. Epub 2015 Mar 14.

PMID:
25770584
10.

Erythroblast apoptosis and microenvironmental iron restriction trigger anemia in the VK*MYC model of multiple myeloma.

Bordini J, Bertilaccio MT, Ponzoni M, Fermo I, Chesi M, Bergsagel PL, Camaschella C, Campanella A.

Haematologica. 2015 Jun;100(6):834-841. doi: 10.3324/haematol.2014.118000. Epub 2015 Feb 24.

11.

Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma.

Mikhael JR, Reeder CB, Libby EN, Costa LJ, Bergsagel PL, Buadi F, Mayo A, Nagi Reddy SK, Gano K, Dueck AC, Stewart AK.

Br J Haematol. 2015 Apr;169(2):219-27. doi: 10.1111/bjh.13296. Epub 2015 Feb 13.

12.

Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma.

Reeder CB, Reece DE, Kukreti V, Mikhael JR, Chen C, Trudel S, Laumann K, Vohra H, Fonseca R, Bergsagel PL, Leis JF, Tiedemann R, Stewart AK.

Br J Haematol. 2014 Nov;167(4):563-5. doi: 10.1111/bjh.13004. Epub 2014 Jun 30. No abstract available.

PMID:
24974945
13.

Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers.

Westwood JA, Matthews GM, Shortt J, Faulkner D, Pegram HJ, Duong CP, Chesi M, Bergsagel PL, Sharp LL, Huhn RD, Darcy PK, Johnstone RW, Kershaw MH.

Leuk Res. 2014 Aug;38(8):948-54. doi: 10.1016/j.leukres.2014.05.010. Epub 2014 Jun 2.

PMID:
24934848
14.

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.

Zhu YX, Braggio E, Shi CX, Kortuem KM, Bruins LA, Schmidt JE, Chang XB, Langlais P, Luo M, Jedlowski P, LaPlant B, Laumann K, Fonseca R, Bergsagel PL, Mikhael J, Lacy M, Champion MD, Stewart AK.

Blood. 2014 Jul 24;124(4):536-45. doi: 10.1182/blood-2014-02-557819. Epub 2014 Jun 9.

15.

Where we were, where we are, where we are going: progress in multiple myeloma.

Bergsagel PL.

Am Soc Clin Oncol Educ Book. 2014:199-203. doi: 10.14694/EdBook_AM.2014.34.199.

16.

Repair of DNA double-strand breaks by templated nucleotide sequence insertions derived from distant regions of the genome.

Onozawa M, Zhang Z, Kim YJ, Goldberg L, Varga T, Bergsagel PL, Kuehl WM, Aplan PD.

Proc Natl Acad Sci U S A. 2014 May 27;111(21):7729-34. doi: 10.1073/pnas.1321889111. Epub 2014 May 12.

17.

The drug vehicle and solvent N-methylpyrrolidone is an immunomodulator and antimyeloma compound.

Shortt J, Hsu AK, Martin BP, Doggett K, Matthews GM, Doyle MA, Ellul J, Jockel TE, Andrews DM, Hogg SJ, Reitsma A, Faulkner D, Bergsagel PL, Chesi M, Heath JK, Denny WA, Thompson PE, Neeson PJ, Ritchie DS, McArthur GA, Johnstone RW.

Cell Rep. 2014 May 22;7(4):1009-19. doi: 10.1016/j.celrep.2014.04.008. Epub 2014 May 9.

18.

CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma.

Murray ME, Gavile CM, Nair JR, Koorella C, Carlson LM, Buac D, Utley A, Chesi M, Bergsagel PL, Boise LH, Lee KP.

Blood. 2014 Jun 12;123(24):3770-9. doi: 10.1182/blood-2013-10-530964. Epub 2014 Apr 29.

19.

TPL2 kinase regulates the inflammatory milieu of the myeloma niche.

Hope C, Ollar SJ, Heninger E, Hebron E, Jensen JL, Kim J, Maroulakou I, Miyamoto S, Leith C, Yang DT, Callander N, Hematti P, Chesi M, Bergsagel PL, Asimakopoulos F.

Blood. 2014 May 22;123(21):3305-15. doi: 10.1182/blood-2014-02-554071. Epub 2014 Apr 10.

20.

Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia.

Ghobrial IM, Witzig TE, Gertz M, LaPlant B, Hayman S, Camoriano J, Lacy M, Bergsagel PL, Chuma S, DeAngelo D, Treon SP.

Am J Hematol. 2014 Mar;89(3):237-42.

PMID:
24716234
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk